Key result
TXA2 receptor antagonists (SQ 28668 and SQ 29548) reduced intracoronary platelet deposition more effectively than the 5-HT2 receptor antagonist ketanserin (p<0.01) in a canine model.
Why the study?
Does a TXA2 receptor antagonist reduce intracoronary platelet deposition more effectively than a 5-HT2 receptor antagonist in a canine model of coronary stenosis?
Population
56 dogs with experimentally stenosed coronary arteries and endothelial injury, 51 of which developed cyclic…
Comparison
TXA2 receptor antagonists SQ 28668 or SQ 29548 vs 5-HT2 receptor antagonist ketanserin and…
Design
Preclinical
Follow-up
1 hour
Authors
Loading...
TXA2 receptor antagonists merit priority in future coronary thrombosis models; leaves open translation to human antithrombotic strategies.
Does a TXA2 receptor antagonist reduce intracoronary platelet deposition more effectively than a 5-HT2 receptor antagonist in a canine model of coronary stenosis?
p-value: p=<0.01
In a canine model of coronary stenosis, TXA2 receptor antagonists were more effective than a 5-HT2 receptor antagonist at reducing intracoronary platelet deposition.
Golino et al. (1988) studied Experimentally stenosed coronary arteries with endothelial injury (n=56). TXA2 receptor antagonists (SQ 28668 and SQ 29548) vs. Ketanserin (5-HT2 receptor antagonist) and control was evaluated on Intracoronary platelet deposition (LAD platelet accumulation ratio) (p=<0.01). TXA2 receptor antagonists (SQ 28668 and SQ 29548) reduced intracoronary platelet deposition more effectively than the 5-HT2 receptor antagonist ketanserin (p<0.01) in a canine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: